• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Role of VAD in the initial treatment of multiple myeloma.

作者信息

Lane Steven W, Gill Devinder, Mollee Peter N, Rajkumar S Vincent

出版信息

Blood. 2005 Nov 15;106(10):3674; author reply 3674-5. doi: 10.1182/blood-2005-07-2610.

DOI:10.1182/blood-2005-07-2610
PMID:16267264
Abstract
摘要

相似文献

1
Role of VAD in the initial treatment of multiple myeloma.
Blood. 2005 Nov 15;106(10):3674; author reply 3674-5. doi: 10.1182/blood-2005-07-2610.
2
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.沙利度胺和地塞米松对比长春新碱-阿霉素-地塞米松（VAD）作为多发性骨髓瘤自体移植预处理的一线治疗的优越性。
Blood. 2005 Jul 1;106(1):35-9. doi: 10.1182/blood-2005-02-0522. Epub 2005 Mar 10.
3
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.沙利度胺、长春新碱、脂质体阿霉素和地塞米松联合用于多发性骨髓瘤的初始治疗（T-VAD多柔比星脂质体方案）：一项II期多中心研究。
Ann Oncol. 2004 Jan;15(1):134-8. doi: 10.1093/annonc/mdh026.
4
Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma.
Expert Rev Anticancer Ther. 2009 Jul;9(7):885-90. doi: 10.1586/era.09.52.
5
First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma.沙利度胺-地塞米松一线疗法用于为有症状的多发性骨髓瘤年轻患者（<61岁）进行自体干细胞移植做准备。
Bone Marrow Transplant. 2005 Aug;36(3):193-8. doi: 10.1038/sj.bmt.1705050.
6
[Hematopoietic stem cell transplantation for multiple myeloma].[多发性骨髓瘤的造血干细胞移植]
Rinsho Ketsueki. 2009 Oct;50(10):1420-6.
7
Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study.一项比较长春新碱、多柔比星（阿霉素）和地塞米松（VAD）化疗与VAD加重组干扰素α-2用于难治性或复发性多发性骨髓瘤的III期研究。一项东部肿瘤协作组的研究。
Am J Clin Oncol. 1995 Dec;18(6):475-80. doi: 10.1097/00000421-199512000-00003.
8
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.骨髓瘤诱导治疗的移植后结局：沙利度胺与地塞米松对比多柔比星、长春新碱及地塞米松用于高剂量美法仑联合自体干细胞支持治疗之前
Am J Hematol. 2007 Dec;82(12):1071-5. doi: 10.1002/ajh.21038.
9
Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.在多发性骨髓瘤自体干细胞移植前，含硼替佐米方案与长春新碱-阿霉素-地塞米松（VAD）作为诱导治疗的回顾性比较。
Jpn J Clin Oncol. 2009 Jul;39(7):449-55. doi: 10.1093/jjco/hyp046. Epub 2009 Jun 1.
10
The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents.新型药物时代诱导方案对新诊断多发性骨髓瘤移植结局的影响。
Bone Marrow Transplant. 2017 Jan;52(1):34-40. doi: 10.1038/bmt.2016.214. Epub 2016 Aug 22.

引用本文的文献

1
The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis.硼替佐米联合地塞米松与沙利度胺联合硼替佐米及地塞米松方案治疗多发性骨髓瘤对血管内皮生长因子的影响：一项荟萃分析。
Biomed Res Int. 2018 Nov 11;2018:3936706. doi: 10.1155/2018/3936706. eCollection 2018.
2
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.肿瘤-基质相互作用在改变药物反应中的作用：挑战与机遇。
Nat Rev Drug Discov. 2013 Mar;12(3):217-28. doi: 10.1038/nrd3870.
3
First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.
一线串联大剂量化疗及自体干细胞移植与单一大剂量化疗及自体干细胞移植治疗多发性骨髓瘤的对照研究系统评价
Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD004626. doi: 10.1002/14651858.CD004626.pub3.
4
Is there a role for 'modified VAD' in the treatment of multiple myeloma?“改良VAD”在多发性骨髓瘤治疗中是否有作用？
Ecancermedicalscience. 2009;3:136. doi: 10.3332/ecancer.2009.136. Epub 2009 Jun 4.
5
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.环磷酰胺、沙利度胺和地塞米松作为新诊断多发性骨髓瘤患者自体干细胞移植的诱导治疗：MRC 骨髓瘤 IX 随机试验结果。
Haematologica. 2012 Mar;97(3):442-50. doi: 10.3324/haematol.2011.043372. Epub 2011 Nov 4.
6
Emerging therapies for multiple myeloma.多发性骨髓瘤的新兴疗法。
Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. doi: 10.1517/14728210802676278.